Home
    • Plans Blog Contact
    ANI Pharmaceuticals Inc logo

    ANI Pharmaceuticals Inc

    ANIP
    Last price US$76.54
    Market cap US$1.7b
    12M price change -14.92%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    ANI Pharmaceuticals Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for ANI Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 07, 2026

    Quarterly result summary

    Revenue was $266M (reported); EPS was $2.21 (reported).

    Revenue $266M reported
    EPS $2.21 reported
    Operating income $40.5M +191% YoY
    Net income $24.7M +189% YoY

    What changed

    • Revenue reported to $266M; EPS reported to $2.21.
    • Operating income +191% YoY to $40.5M.
    • Net income +189% YoY to $24.7M.

    Capital return

    Board authorized up to $100M of additional repurchases.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 07, 2026 SEC filing 8-K Aug 07, 2026 Earnings material Earnings release Aug 07, 2026 SEC filing 10-Q May 08, 2026 SEC filing 8-K May 08, 2026 Earnings release Earnings release May 08, 2026 SEC filing 10-K Feb 27, 2026 SEC filing 8-K Feb 27, 2026 Earnings release Earnings release Feb 27, 2026 Earnings material Earnings release Jan 12, 2026 SEC filing 8-K Jan 12, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    ANI Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.09/5
    ANI Pharmaceuticals Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ANI Pharmace... ANIP US$1.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.20/5
    ANI Pharmaceuticals Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ANI Pharmace... ANIP US$1.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 1.80/5
    ANI Pharmaceuticals Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    ANI Pharmace... ANIP US$1.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    ANI Pharmaceuticals Inc logo

    ANI Pharmaceuticals Inc

    US$76.54

    US$118.60

    +55.0% vs price

    US$1.7b

    -2.19%

    -14.92%